FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807432910> ?p ?o ?g. }

• W2807432910 endingPage "406" @default.
• W2807432910 startingPage "399" @default.
• W2807432910 abstract "Purpose The objective of this study was to describe the outcome and prognostic factors for adults treated for localized myxofibrosarcoma. Methods and Materials We conducted a retrospective multicenter study of 425 nonmetastatic patients who underwent surgery between January 1996 and December 2015 in French National Group and were enrolled in the Conticabase. Pathologic diagnosis was systematically reviewed by expert pathologists. The endpoints were relapse-free and metastasis-free survival. Log-rank tests and Cox models have been used to identified prognostic factors. Results Median age was 66 years; 53% were males; 85% of cases occurred in limbs or superficial trunk; median size was 60 mm; 47% and 39% were grades 2 and 3, respectively; 66% had R0 resection and 34% R1 resection. Adjuvant radiation therapy was given to 65% of patients, neoadjuvant radiation therapy to 3%, neoadjuvant chemotherapy to 7%, and adjuvant chemotherapy to 13%. The median follow-up was 51 months. The 5-year local relapse–free survival was 67%; independent prognostic factors for local relapse were R1 resection (hazard ratio [HR] = 1.26; P = .001) and adjuvant radiation therapy (HR = 0.35; P = .0001) (ie, R1 resection and no adjuvant radiation therapy increase the hazard ratio). In stratified analysis, adjuvant radiation therapy was beneficial after R0 resection (P = .0020) and after R1 resection (P = .0001). The 5-year overall survival was 80%. The 5-year metastasis-free survival was 83%. Independent prognostic factors for metastatic relapse were grade 3 disease (HR = 1.975; P = .0001) and tumor size (HR = 1.006; P = .001). Conclusions This large series of myxofibrosarcoma confirms the high rate of local relapse. Combination of R0 resection and adjuvant radiation therapy provided the best local control. In parallel with an increasing rate of R0 resection and adjuvant radiation therapy, we observed a constant improvement in both metastatic and local relapse–free survival during the study. The objective of this study was to describe the outcome and prognostic factors for adults treated for localized myxofibrosarcoma. We conducted a retrospective multicenter study of 425 nonmetastatic patients who underwent surgery between January 1996 and December 2015 in French National Group and were enrolled in the Conticabase. Pathologic diagnosis was systematically reviewed by expert pathologists. The endpoints were relapse-free and metastasis-free survival. Log-rank tests and Cox models have been used to identified prognostic factors. Median age was 66 years; 53% were males; 85% of cases occurred in limbs or superficial trunk; median size was 60 mm; 47% and 39% were grades 2 and 3, respectively; 66% had R0 resection and 34% R1 resection. Adjuvant radiation therapy was given to 65% of patients, neoadjuvant radiation therapy to 3%, neoadjuvant chemotherapy to 7%, and adjuvant chemotherapy to 13%. The median follow-up was 51 months. The 5-year local relapse–free survival was 67%; independent prognostic factors for local relapse were R1 resection (hazard ratio [HR] = 1.26; P = .001) and adjuvant radiation therapy (HR = 0.35; P = .0001) (ie, R1 resection and no adjuvant radiation therapy increase the hazard ratio). In stratified analysis, adjuvant radiation therapy was beneficial after R0 resection (P = .0020) and after R1 resection (P = .0001). The 5-year overall survival was 80%. The 5-year metastasis-free survival was 83%. Independent prognostic factors for metastatic relapse were grade 3 disease (HR = 1.975; P = .0001) and tumor size (HR = 1.006; P = .001). This large series of myxofibrosarcoma confirms the high rate of local relapse. Combination of R0 resection and adjuvant radiation therapy provided the best local control. In parallel with an increasing rate of R0 resection and adjuvant radiation therapy, we observed a constant improvement in both metastatic and local relapse–free survival during the study." @default.
• W2807432910 created "2018-06-13" @default.
• W2807432910 creator A5000010493 @default.
• W2807432910 creator A5004321308 @default.
• W2807432910 creator A5005548663 @default.
• W2807432910 creator A5012250582 @default.
• W2807432910 creator A5023740879 @default.
• W2807432910 creator A5034788813 @default.
• W2807432910 creator A5042202815 @default.
• W2807432910 creator A5047514488 @default.
• W2807432910 creator A5052242950 @default.
• W2807432910 creator A5057378575 @default.
• W2807432910 creator A5061469135 @default.
• W2807432910 creator A5061716442 @default.
• W2807432910 creator A5065856111 @default.
• W2807432910 creator A5066266071 @default.
• W2807432910 creator A5075953565 @default.
• W2807432910 creator A5080620486 @default.
• W2807432910 creator A5082347575 @default.
• W2807432910 creator A5087184053 @default.
• W2807432910 creator A5089433083 @default.
• W2807432910 creator A5091721810 @default.
• W2807432910 date "2018-10-01" @default.
• W2807432910 modified "2023-10-16" @default.
• W2807432910 title "Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy" @default.
• W2807432910 cites W1584305089 @default.
• W2807432910 cites W1974959460 @default.
• W2807432910 cites W1995258857 @default.
• W2807432910 cites W2052002153 @default.
• W2807432910 cites W2052572216 @default.
• W2807432910 cites W2054622999 @default.
• W2807432910 cites W2062865799 @default.
• W2807432910 cites W2065614082 @default.
• W2807432910 cites W2122748438 @default.
• W2807432910 cites W2123113815 @default.
• W2807432910 cites W2160253626 @default.
• W2807432910 cites W2166178367 @default.
• W2807432910 cites W2233546673 @default.
• W2807432910 cites W2342863481 @default.
• W2807432910 cites W2477628106 @default.
• W2807432910 cites W2658840012 @default.
• W2807432910 cites W2775279403 @default.
• W2807432910 cites W4252350962 @default.
• W2807432910 doi "https://doi.org/10.1016/j.ijrobp.2018.05.055" @default.
• W2807432910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30191871" @default.
• W2807432910 hasPublicationYear "2018" @default.
• W2807432910 type Work @default.
• W2807432910 sameAs 2807432910 @default.
• W2807432910 citedByCount "19" @default.
• W2807432910 countsByYear W28074329102018 @default.
• W2807432910 countsByYear W28074329102019 @default.
• W2807432910 countsByYear W28074329102020 @default.
• W2807432910 countsByYear W28074329102021 @default.
• W2807432910 countsByYear W28074329102022 @default.
• W2807432910 countsByYear W28074329102023 @default.
• W2807432910 crossrefType "journal-article" @default.
• W2807432910 hasAuthorship W2807432910A5000010493 @default.
• W2807432910 hasAuthorship W2807432910A5004321308 @default.
• W2807432910 hasAuthorship W2807432910A5005548663 @default.
• W2807432910 hasAuthorship W2807432910A5012250582 @default.
• W2807432910 hasAuthorship W2807432910A5023740879 @default.
• W2807432910 hasAuthorship W2807432910A5034788813 @default.
• W2807432910 hasAuthorship W2807432910A5042202815 @default.
• W2807432910 hasAuthorship W2807432910A5047514488 @default.
• W2807432910 hasAuthorship W2807432910A5052242950 @default.
• W2807432910 hasAuthorship W2807432910A5057378575 @default.
• W2807432910 hasAuthorship W2807432910A5061469135 @default.
• W2807432910 hasAuthorship W2807432910A5061716442 @default.
• W2807432910 hasAuthorship W2807432910A5065856111 @default.
• W2807432910 hasAuthorship W2807432910A5066266071 @default.
• W2807432910 hasAuthorship W2807432910A5075953565 @default.
• W2807432910 hasAuthorship W2807432910A5080620486 @default.
• W2807432910 hasAuthorship W2807432910A5082347575 @default.
• W2807432910 hasAuthorship W2807432910A5087184053 @default.
• W2807432910 hasAuthorship W2807432910A5089433083 @default.
• W2807432910 hasAuthorship W2807432910A5091721810 @default.
• W2807432910 hasConcept C10515644 @default.
• W2807432910 hasConcept C126322002 @default.
• W2807432910 hasConcept C141071460 @default.
• W2807432910 hasConcept C143998085 @default.
• W2807432910 hasConcept C167135981 @default.
• W2807432910 hasConcept C207103383 @default.
• W2807432910 hasConcept C2776694085 @default.
• W2807432910 hasConcept C2777863537 @default.
• W2807432910 hasConcept C2777982462 @default.
• W2807432910 hasConcept C44249647 @default.
• W2807432910 hasConcept C50382708 @default.
• W2807432910 hasConcept C509974204 @default.
• W2807432910 hasConcept C71924100 @default.
• W2807432910 hasConceptScore W2807432910C10515644 @default.
• W2807432910 hasConceptScore W2807432910C126322002 @default.
• W2807432910 hasConceptScore W2807432910C141071460 @default.
• W2807432910 hasConceptScore W2807432910C143998085 @default.
• W2807432910 hasConceptScore W2807432910C167135981 @default.
• W2807432910 hasConceptScore W2807432910C207103383 @default.
• W2807432910 hasConceptScore W2807432910C2776694085 @default.
• W2807432910 hasConceptScore W2807432910C2777863537 @default.
• W2807432910 hasConceptScore W2807432910C2777982462 @default.

• next